Suet L. Felce

Old Road Campus
Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation.

HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation.

Journal: Science immunology

Published: June 30, 2023

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.

Journal: iScience

Published: February 08, 2023

SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses.

SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses.

Journal: Heliyon

Published: September 06, 2022

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.

Journal: Nature immunology

Published: July 19, 2021

RNA-Seq analysis of early transcriptional responses to activation in the leukaemic Jurkat E6.1 T cell line.

RNA-Seq analysis of early transcriptional responses to activation in the leukaemic Jurkat E6.1 T cell line.

Journal: Wellcome open research

Published: June 07, 2021

Increasing LFA-1 Expression Enhances Immune Synapse Architecture and T Cell Receptor Signaling in Jurkat E6.1 Cells.

Increasing LFA-1 Expression Enhances Immune Synapse Architecture and T Cell Receptor Signaling in Jurkat E6.1 Cells.

Journal: Frontiers in cell and developmental biology

Published: February 27, 2021

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.

Journal: Frontiers in oncology

Published: December 13, 2019

Target Identification Using Chemical Probes.

Target Identification Using Chemical Probes.

Journal: Methods in enzymology

Published: November 05, 2018

Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.

Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.

Journal: SLAS discovery : advancing life sciences R & D

Published: October 26, 2018

Discovery of an MLLT1/3 YEATS Domain Chemical Probe.

Discovery of an MLLT1/3 YEATS Domain Chemical Probe.

Journal: Angewandte Chemie (International ed. in English)

Published: September 14, 2018

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Journal: Haematologica

Published: January 15, 2016

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Journal: Leukemia

Published: September 04, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026